The Hopkins Lupus Cohort is a unique 25 year, 2000 SLE patient longitudinal cohort in which patients are followed by protocol every 3 months, allowing study of time-varying (lupus activity, cardiovascular risk factors and, treatment) variables: 1) In the last RO-1 we successfully developed and published computed tomography angiography (CTA) for detection of non-calcified plaque in SLE and showed that it was associated with same day measures of SLE activity. In this RO-1, we will determine predictors of non-calcified plaque changes over time. We will bring an automated measure of non-calcified and calcified plaque burden to the clinic. 2) In the last RO-1 we successfully developed a consortium of U.S. sites interested in urine biomarkers of lupus nephritis activity, and discovered and published new biomarkers including urinary VCAM-1. In this RO-1 we have enlarged the consortium, arranged collaboration with the Glaxo Smith Kline belimumab lupus nephritis clinical trial to obtain longitudinal samples, and have begun our own urinary proteomics discovery program. We have already successfully brought urinary TWEAK to clinical trial stage, and anticipate bringing a panel of urinary biomarkers to the clinic for identification of lupus nephrits activity and prediction of treatment outcome. 3) In a past collaboration with Biogen Idec we found that BAFF and neutrophil gene signatures associate with same day SLE activity and predict activity over the next year. In this RO-1, we will continue that collaboration and determine whether these gene signatures are invariant in an individual or whether they change over time. If they change, we will evaluate the contributions of treatments and other variables. These investigations will demonstrate the utility of these signatures in indicating and predicting disease activity over time, so that they can be used in the clinic and in clinical trials.
The Hopkins Lupus Cohort is a longitudinal study of over 2,000 SLE patients followed every 3 months by protocol. This RO-1 explores three new outcomes: 1) predicting how a measure of coronary artery atherosclerosis, non-calcified plaque, changes over time;2) tracking renal activity through urine biomarkers and 3) determining how gene signatures contribute to disease activity and organ damage.
|Hardt, Uta; Larsson, Anders; Gunnarsson, Iva et al. (2018) Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Res Ther 20:36|
|Pejchinovski, M; Siwy, J; Mullen, W et al. (2018) Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus 27:6-16|
|Little, Jayne; Parker, Ben; Lunt, Mark et al. (2018) Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57:677-687|
|Iftikhar, Mustafa; Kaur, Ramandeep; Nefalar, April et al. (2018) MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. Retina :|
|Merrill, Joan T; Petri, Michelle A; Buyon, Jill et al. (2018) Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 5:e000263|
|Eudy, Amanda M; Siega-Riz, Anna Maria; Engel, Stephanie M et al. (2018) Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis 77:855-860|
|Davidson, Julie E; Fu, Qinggong; Ji, Beulah et al. (2018) Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. J Rheumatol 45:671-677|
|Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Petri, Michelle et al. (2018) Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. J Rheumatol 45:393-396|
|Costedoat-Chalumeau, Nathalie; Houssiau, Frédéric; Izmirly, Peter et al. (2018) A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther 103:1074-1082|
|Giannakou, Ioanna; Chatzidionysiou, Katerina; Magder, Laurence S et al. (2018) Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Sci Med 5:e000287|
Showing the most recent 10 out of 220 publications